Does glycosylation modify the pharmacokinetic behaviour of cytokines?
Considering that glycosylation may affect the affinity of cytokines for their specific receptors, some pharmacokinetic differences are to be expected when administering cytokines either in the glycosylated or in the deglycosylated form. Watts and colleagues examined the pharmacokinetic behavior of lenograstim and filgrastim (non-glycosylated G-CSF) in healthy male volunteers [29]. Elimination half-lives for filgrastim and lenograstim were 2.75 hours and 2.95 hours respectively, thus providing no evidence of statistical difference. In contrast, there was a higher area under the curve with filgrastim in comparison with lenograstim (> 20%, p < 0.05). A recent meta-analysis underlines the fact that EPO reduces the odds of transfusion for cancer patients undergoing therapy [30]. Unfortunately, there are no comparative data available concerning the metabolism of the two cytokines which seem to have opposing effects as concerns their respective biological activity. This suggests that the diff
Related Questions
- I have taken Organizational Behaviour and Marketing courses at another post secondary institution. How do I find out if I qualify for an exemption from Organizational Behaviour and Marketing?
- Does glycosylation modify the pharmacokinetic behaviour of cytokines?
- Does glycosylation affect cytokine stability?
